| HOME >> BIOLOGY >> TECHNOLOGY |
----------- ------- -------
BALANCE AT DECEMBER 31, 2006 220,124,349 1,072 136,611
CHANGES DURING THE SIX MONTHS
ENDED JUNE 30, 2007:
Comprehensive loss - loss for
the period -- -- --
Non-employee stock option
compensation expenses -- -- 5
Employee stock option compensation
expenses -- -- 964
Exercise of stock options 30,000 (**) 3
----------- ------- --------
BALANCE AT JUNE 30, 2007 220,154,349 1,072 137,583
=========== ======= ========
Deficit
accumulated
during the
development
stage Total
--------- ---------
BALANCE AT DECEMBER 31, 2006 (114,923) 22,760
CHANGES DURING THE SIX MONTHS
ENDED JUNE 30, 2007:
Comprehensive loss - loss for the
period (14,649) (14,649)
Non-employee stock option
compensation expenses -- 5
Employee stock option compensation
expenses -- 964
Exercise of stock options -- 3
--------- ---------
BALANCE AT JUNE 30, 2007 (129,572) 9,083
========= =========
(**) Represents an amount less than $1,000.
<SOURCE XTL Biopharmaceuticals Ltd![]() Copyright©2007 PR Newswire. |